Third COVID-19 vaccine dose boosts antibody function in Rwandans with high HIV viral load

Swan, Cynthia L.; Dushimiyimana, Valentine; Ndishimye, Pacifique; Buchanan, Rachelle; Yourkowski, Anthony; Semafara, Sage; Nsanzimana, Sabin; Francis, Magen E.; Thivierge, Brittany; Lew, Jocelyne; Facciuolo, Antonio; Gerdts, Volker; Falzarano, Darryl; Sjaarda, Calvin; Kelvin, David J.; Bitunguhari, Leopold; Kelvin, Alyson A.

doi:10.1016/j.isci.2023.107959

Cited by 1 publication

(1 citation statement)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…32 Similarly, HIV viral load was identified as influential independent factors affecting immune seropositivity in Chinese PLWH, which were also proved in Rwandans. 33 Although PLWH may experience somewhat inferior protection from vaccination compared to HIV-negative individuals beyond the 3-month mark, sufficient protection against the WT virus is still maintained for up to 6 months.…”

Section: Factors Associated With Immunogenicity and Correlation Of In...mentioning

confidence: 99%

Safety and immunogenicity of homologous prime‐boost CoronaVac vaccine in people living with HIV in China: A multicenter prospective cohort study

Wang,

Lan,

Qiao

et al. 2024

Journal of Medical Virology

View full text Add to dashboard Cite

People living with HIV (PLWH) are particularly vulnerable to SARS‐CoV‐2. This multicentre prospective cohort study evaluated the long‐term immunogenicity and safety of a third homologous dose of Sinovac CoronaVac in PLWH in China. A total of 228 PLWH and 127 HIV‐negative controls were finally included and followed up for 6 months. Fewer participants reported mild or moderate adverse reactions, and no serious adverse events were observed. The median levels of neutralizing antibodies (nAbs) and immunoglobulin G against the receptor‐binding domain of the spike protein (S‐IgG) in PLWH (655.92 IU/mL, IQR: 175.76–1663.55; 206.83 IU/mL, IQR: 85.20–397.82) were comparable to those in control group (1067.16 IU/mL, IQR: 239.85–1670.83; 261.70 IU/mL, IQR: 77.13–400.75), and reached their peak at 4 weeks, exhibiting a delayed peak pattern compared to the 2‐week peak in control group. After then, the immune titres gradually decreased over time, but most participants still maintained positive seroconversion at the 6‐month mark. Multivariable generalized estimating equation analysis indicated that CD4+T cell count, HIV viral load, and antiretroviral therapy (ART) were independent factors strongly associated with immune response (each p < 0.05). We suggested that PLWH should maintain well‐controlled HIV status through ART and receive timely administration of the second booster dose for optimal protection.

show abstract

Section: Factors Associated With Immunogenicity and Correlation Of In...mentioning

confidence: 99%

Safety and immunogenicity of homologous prime‐boost CoronaVac vaccine in people living with HIV in China: A multicenter prospective cohort study

Wang,

Lan,

Qiao

et al. 2024

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

Third COVID-19 vaccine dose boosts antibody function in Rwandans with high HIV viral load

Cited by 1 publication

References 40 publications

Safety and immunogenicity of homologous prime‐boost CoronaVac vaccine in people living with HIV in China: A multicenter prospective cohort study

Safety and immunogenicity of homologous prime‐boost CoronaVac vaccine in people living with HIV in China: A multicenter prospective cohort study

Contact Info

Product

Resources

About